Renal Cell Carcinoma Metastatic clinical trials

Explore recruiting renal cell carcinoma metastatic clinical trials.

Recruiting renal cell carcinoma metastatic studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Renal Cell Carcinoma Metastatic trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Multicentric trial evaluating the correlation between early PSMA-PET change and response to systemic treatment for first-line metastatic clear cell Renal Carcinoma Cell.

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

EORTC-2361-GUCG: Phase II trial evaluating the efficacy of 177Lutetium-PSMA treatment in patients with metastatic clear cell Renal Carcinoma Cell with progressive disease on first-line or second-line systemic treatment (RENALUT)

Spain, France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC

Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

C6461008 - AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

Germany, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A study evaluating the safety, tolerability, pharmacokinetics, and activity of RO7566802 given alone and in combination with atezolizumab in patients with locally advanced or metastatic solid tumor malignancies

Spain, Czechia

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Czechia, Spain, Belgium, France, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Renal Cell Carcinoma Metastatic trials by city

Renal Cell Carcinoma Metastatic in Toronto Renal Cell Carcinoma Metastatic in Vancouver Renal Cell Carcinoma Metastatic in Montreal Renal Cell Carcinoma Metastatic in Calgary Renal Cell Carcinoma Metastatic in Edmonton Renal Cell Carcinoma Metastatic in Ottawa Renal Cell Carcinoma Metastatic in Winnipeg Renal Cell Carcinoma Metastatic in Quebec City Renal Cell Carcinoma Metastatic in Hamilton Renal Cell Carcinoma Metastatic in Kitchener Renal Cell Carcinoma Metastatic in London Renal Cell Carcinoma Metastatic in Halifax Renal Cell Carcinoma Metastatic in New York Renal Cell Carcinoma Metastatic in Los Angeles Renal Cell Carcinoma Metastatic in Chicago Renal Cell Carcinoma Metastatic in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease